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Abstract
With the development of highly active antiretroviral therapy,
chronic kidney disease has become a prominent cause of
morbidity in individuals infected by HIV. Because serum
creatinine has significant limitations in this specific popula-
tion, cystatin C is emerging as a promising biomarker for
both the evaluation of glomerular filtration rate (GFR) and
the detection of drug-induced kidney injury. Along with
renal function, serum cystatin C concentration is associated
with several biological parameters such as C-reactive pro-
tein, HIV viral load and CD41 cells count. All these deter-
minants of cystatin C are, however, more or less independent
of GFR. Studies evaluating the accuracy of cystatin C for
estimating GFR in the setting of HIV infection are scarce and
methodology is often questionable (lack of reference method
or inadequate statistical analyses). Thus far, data are insuffi-
cient to encourage the use of cystatin C or cystatin C-based
equations to estimate GFR in the HIV-infected population.
Further research is needed to explore the clinical utility of
cystatin C in this setting. Beyond the use of cystatin C as a
GFR marker, future studies will have to evaluate its role as a
predictor of patient outcome, particularly in regard to cardi-
ovascular morbi-mortality.
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Introduction
The United Nations Programme on HIV/AIDS estimated
that 33.3 million people were living with a HIV infection in
2009 [1]. The development of highly active antiretroviral
therapy (HAART) has resulted in improved survival
among HIV-seropositive individuals. With advancing
age and HAART-related metabolic effects (diabetes [2],
hypertension [3], and dyslipidaemia [4]), chronic kidney
disease (CKD) has become one of the major comorbidities
in HIV-seropositive individuals [5]. The real prevalence of
CKD in HIV patients is still, however, questioned. In a
retrospective chart review, Fernando et al. [6] found
evidence of CKD in 24% of the patients and CKD Stage
3 [estimated glomerular filtration rate (eGFR) <60 mL/
min/1.73 m2] or higher in 10% of the patients. Overton
et al. [7] found a prevalence of Stage 3 CKD of 7.4%
in HIV-infected subjects versus 2.1% in controls. Crum-
Cianflone et al. [8] found a lower prevalence of CKD Stage
3 (3%). Importantly, in the latter study, patients were rela-
tively young, had no comorbidities and no specific evalua-
tion for proteinuria. Campbell et al. [9] found similar
results with a prevalence of 2.4% for Stage 3 CKD.
Risk factors for CKD in HIV-infected patients vary ac-
cording to the studies but include female sex, black race [10],
AIDS, low CD41 lymphocyte count, older age, hepatitis C
virus (HCV) co-infection, hypertension, diabetes mellitus
[6, 7] and injecting drug use [11]. Exposure to HAART is
also associated with an increased risk for CKD, tenofovir,
didanosine, atazanavir, lopinavir and indinavir being the
most frequently incriminated anti-retroviral drugs [12, 13].
Moreover, similar to the general population, CKD is
associated with an increased risk of both mortality [14, 15]
and cardiovascular events (CVE) [16] in HIV-seropositive
individuals. In HIV-infected women, Szczech et al. [17]
observed that proteinuria was associated with an increased
risk of AIDS-defining illness {hazard ratio (HR) ¼ 1.37
[95% confidence interval (95% CI) 1.01–1.81]}. Proteinu-
ria and elevated creatinine level were also associated with
an increased risk of mortality with a HR of 1.35 (95% CI
1.01–1.81) and 1.72 (95% CI 1.09–2.70), respectively.
These associations were curiously stronger than the associ-
ation of low CD41 lymphocyte count with AIDS-defining
illness and death in this cohort [17]. In multivariate analy-
sis, the odds ratio for CVE was 1.2 (95% CI 1.1–1.4)
for every 10 mL/min/1.73 m2 decrease in eGFR. These
results can, however, be criticized because it has been
shown in the general population that the association be-
tween glomerular filtration rate (GFR) and CVE is a
graded, but not a linear one [18]. Because of the growing
prevalence and burden of CKD in HIV-infected patients,
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screening, prevention and management of CKD have be-
come a key challenge in this population. In 2005, the Infec-
tious Diseases Society of America published guidelines for
CKD screening in HIV-infected patients. According to these
recommendations, kidney function should be assessed at ini-
tial diagnosis by measuring proteinuria and estimating GFR.
In cases where CKD risk factors are present, kidney function
should be assessed every 6 months. Utilization of creatinine-
based estimates, and particularly the Modification Diet in
Renal Disease (MDRD) study equation, is recommended
[19, 20]. This latest recommendation has, however, to be
challenged by the various limitations inherent to the use of
serum creatinine as a marker of GFR. Variations in genera-
tion, secretion and extra-renal elimination of creatinine have
been extensively described in different populations [21]. This
holds particularly true for HIV-infected patients for whom
many specific factors are likely to impact the relation between
serum creatinine and GFR. As a result, serum cystatin C is
being touted as an alternative to serum creatinine with the
potential to more accurately account for different degrees of
renal impairment [22, 23]. Cystatin C level has also been
shown in the general population to be more closely associated
than creatinine (and creatinine-based equations) with CVE,
all-cause mortality and incident end-stage renal disease [24–
26]. The mechanism of this association between cystatin C
and outcomes—CVE and mortality—is not fully understood.
It might, at least in part, have to do with the non-GFR deter-
minants of cystatin C level, but this is still subject to debate.
Whatever the mechanisms underlying this association, cysta-
tin C can also be seen as a potential biomarker that may better
predict outcomes in the high-risk HIV patient [27].
Serum creatinine: an imperfect marker of renal
function in HIV-infected individuals
Creatinine is freely filtered by the glomerulus and secreted
by the proximal tubular cells. Creatinine level can be af-
fected at three levels: creatinine generation, tubular secre-
tion and extra-renal elimination. Creatinine is the catabolic
end product of creatine. Ninety-eight percent of creatinine
is generated from muscle. Serum creatinine concentration
is thus highly dependent on muscle mass [28, 29]. In
HIV-infected patients, creatinine generation is expected
to decrease for numerous reasons (see Table 1). HIV in-
fection induces modifications of the body composition. For
example, HIV-infected men have a lower fat-free mass
compared to matched healthy controls [30, 31]. HIV infec-
tion can also lead to wasting syndromes responsible for
severe depletion in lean and fat tissue [32]. Similarly,
HIV-infected subjects are more often malnourished than is
the general population [33]. By further modifying body
composition, lipodystrophy induced by HAART may alter
the association between serum creatinine and GFR.
Additionally, creatinine production in patients with liver
disease is decreased [34]. Co-infection with viral hepatitis
is frequent (roughly one-third of patients are co-infected
with HCV or hepatitis B virus in Western countries)
[35, 36]. In HIV-infected individuals, HCV co-infection is
associated with a decrease in serum creatinine level [37, 38].
In addition, liver cirrhosis is associated with malnutrition
and protein depletion [39]. Given that HCV is another risk
for CKD, early diagnosis remains critical in these patients.
Besides the problem of creatinine generation, change in
creatinine metabolism might also explain the difficulty to
rely on serum creatinine for estimating GFR in HIV pa-
tients. For instance, the use of trimethoprim/sulfamethox-
azole (TMP/SMX) is recommended in primary and
secondary prophylaxis of infections due to Toxoplasma
gondii and Pneumocystis jiroveci [40, 41]. Specifically,
TMP inhibits creatinine secretion by the tubules, inducing
an increase in serum creatinine independent of any decrease
in GFR [42]. Serum creatinine increase after trimethoprim
intake varies from 15 to 30% [43, 44].
Given the numerous factors specific to HIV infection that
may influence creatinine level, two recent US cohort studies
have compared serum creatinine in HIV and control non-
HIV individuals. In the Fat Redistribution And Metabolic
change (FRAM) study, 519 HIV-positive patients were com-
pared with 290 healthy controls from the Coronary Artery
Risk Development in Young Adults (CARDIA) study [45].
There was no significant difference in creatinine level be-
tween the two groups. However, the two groups were differ-
ent for several characteristics—notably a higher prevalence
of HCV infection, hypertension, diabetes and proteinuria in
the HIV-infected populations—which might have masked a
lower creatinine level. In the second study, 250 HIV-infected
subjects from the Nutrition for Healthy Living (NFHL) co-
hort were compared with 2628 persons matched for age, race
and sex from the National Health and Nutrition Examination
Survey (NHANES) [38]. Serum creatinine level was found to
be significantly lower in the NFHL cohort. In the same line,
Mauss et al. [46] compared kidney function between 261
HIV-seropositive patients naı¨ve to anti-retroviral therapy
with 193 healthy controls. While they found no significant
difference between the two groups for serum creatinine, they
did observe a trend towards an association between lower
serum creatinine and HIV seropositivity after adjustment for
sex, age and body mass index [46]. In a retrospective study,
Overton et al. [7] compared prevalence of kidney function
Table 1. Principal factors influencing serum creatinine level in HIV-infected subjects
Effects on creatinine HIV
Lean mass Increase in creatinine production Decrease in lean mass: AIDS wasting syndrome, mitochondrial
toxicity of HAART
Dietary intake Increase in creatinine production Strong prevalence of malnutrition in HIV-infected subjects
Liver disease Decrease in creatine production Prevalence of HCV infection in HIV-infected subjects around 30%
African American ethnicity Increase in creatinine production
Reduction of the tubular excretion of creatinine
Trimethoprim Reduction of the tubular excretion of creatinine Pneumocystis jiroveci infections prophylaxis
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between 845 HIV-infected subjects with 845 HIV-negative
subjects from the NHANES cohort. The prevalence of
chronic renal failure (eGFR<60 mL/min/1.73 m2) and serum
creatinine level were significantly greater in HIV-infected
subjects than in controls (7.4 versus 2.1%, 1.13 versus
0.95 mg/dL, respectively). HIV-infected subjects had more
risk factors for CKD, such as hypertension and hepatitis in-
fection and more often had a history of injecting drug use
(IDU). These studies yielded different results and drawing
definitive conclusion are thus difficult. Obviously, the princi-
pal limitation of these studies is the absence of GFR measure-
ment by a gold standard method. Moreover, due to the great
prevalence of viral hepatitis and IDU in the HIV-infected
population, matching controls with HIV-infected subjects,
remains difficult.
Serum cystatin C in HIV-positive subjects: the
ideal GFR marker?
Cystatin C is a low-molecular weight protein produced by
all nucleated cells, freely filtered in the glomerulus and
catabolyzed by tubular cells [47]. Only small amounts are
found in urine in the physiological state. Limitations of
serum creatinine due to creatinine extra-renal excretion or
tubular secretion are thus not present with cystatin C. How-
ever, it remains important to study muscular mass and
other factors, which could influence cystatin C levels
independently of GFR. Two important studies in HIV-
negative subjects have examined the factors that affect
serum levels of cystatin C, independently of GFR. They
both identified age, gender, and C-reactive protein (CRP)
level in serum [48, 49] (see Table 2). In one, current smoking
was also associated with an increase in serum cystatin C
level. In another study, MacDonald et al. [51] demonstrated
by measuring GFR by inulin clearance and evaluating body
composition by dual X-ray absorptiometry that cystatin C is
also affected by lean mass. However, the magnitude of the
associations with height and weight is greater for serum
creatinine than for serum cystatin C [49]. Cystatin C is thus
clearly far less dependent on muscular mass than creatinine.
Moreover, in a population-based study (Multi-Ethnic Study
of Atherosclerosis, MESA Study), Kramer et al. showed no
significant difference in mean cystatin C levels between
African Americans and Caucasians [52] although serum cre-
atinine strongly varies according to ethnicity (also probably
reflecting difference in muscular mass according to ethnic-
ity) [53]. The influence of these factors can be, once again,
critical in HIV-infected subjects.
The association of cystatin C to CRP is potentially prob-
lematic in HIV patients. Markers of inflammation are indeed
chronically elevated in HIV-positive adults. High-sensitivity
(hs) CRP was found to be 55% higher in HIV-positive
patients from the Strategies for Management of Anti Retro-
viral Therapy (SMART) study as compared to controls from
the MESA and CARDIA studies [54]. Likewise, cystatin C
was found to be 27.2% higher in the SMART study group.
The association between hs-CRP and cystatin C level is,
however, inconsistent. In the Jaroszewicz study [55], while
CRP and cystatin C levels were significantly greater in HIV-
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aNephroTest, the NephroTest initiative is a prospective hospital-based ongoing cohort that began in 2000, enrolling patients with all diagnoses of CKD
Stages 2–5 referred for extensive work-up by two nephrology departments. Data included in this study were collected between 2000 and 2004; AASK,
African American Study of Kidney Diseases and Hypertension; BMI, body mass index; CSG, Collaborative Study Group: Captopril in Diabetic
Nephropathy Study; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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positive subjects, no significant correlation between CRP
and cystatin C was found. Moreover, Estrella et al. [56]
published a cross-sectional study with 783 HIV-infected pa-
tients from the Multicenter AIDS Cohort Study (MACS) and
150 HIV-negative subjects. eGFR based on cystatin C was
lower in the HIV1 group than in the controls, while eGFR
based on creatinine was not different. eGFR based on crea-
tinine and cystatin C were both influenced by age, AIDS
condition and proteinuria. In the adjusted model, eGFR
based on cystatin C was not influenced by CRP level. The
precise role played by other confounders (like renal insuffi-
ciency or smoking status) in the relation between serum
cystatin C and CRP requires further evaluation because
CKD status, per se, is associated with ‘microinflammation’.
Non-GFR factors potentially influencing cystatin C lev-
els have also been studied in the specific population of HIV
patients. HIV replication may affect serum cystatin C level.
In 922 patients from the FRAM study cohort, Choi et al.
[27] observed that HIV-1 viral load was higher in the group
of patients with an eGFR based on cystatin C (eGFRcys)
level <60 mL/min/1.73 m2 than in the group of patients
with a greater eGFRcys. This association was not observed
in another study with subjects from the same cohort or in the
SMART trial study cohort [45, 54]. The SMART trial was
designed to compare two strategies of anti-retroviral treat-
ment [57]. In the first arm (drug conservation), treatment was
guided by immunological response and HAART was stop-
ped when CD41 lymphocyte count was >350/mm3. In the
second arm (viral suppression), HAART was maintained
[58]. The interruption of HAART in the SMART study
was associated with an increase in HIV-1 viral load and
cystatin C [59]. A higher viral load at baseline and an in-
crease in HIV-1 viral load during follow-up were associated
with an increase in cystatin C level in the FRAM study [60].
In the MACS cohort, a decrease in eGFRcys is associated
with an increase in HIV viral load [56]. In a study of
validation of estimated renal function by cystatin C-based
equations, higher HIV-1 viral load was associated with
higher cystatin C level independently of measured GFR.
This analysis was performed in only 15 patients in whom
GFR was measured by 51Cr-ethylenediaminetetraacetic acid
(51Cr-EDTA) clearance [61]. Because viral load is also a
strong predictor of GFR and because GFR was only esti-
mated, not measured, in most of these studies, it cannot be
concluded from these studies that the potential effect of viral
load on cystatin C level is really independent of GFR
variation.
Other possible factors related to HIV infection might
affect cystatin C level: HIV-infected macrophages produc-
ing less cystatin C than uninfected ones [62] and CD41
lymphocyte count (most studies showing an association
between a lower count of CD41 cells and a higher cystatin
C level [27, 38, 45, 63]). Here again, some discrepancies
exist across studies. In the SMART trial, cystatin C at base-
line was not correlated to CD41 cells, but an increase in
cystatin C during follow-up was associated with a lower
CD41 count [59]. Two others studies did not show a sig-
nificant correlation between CD41 cells and cystatin C
level [55, 64]. Once again, advanced HIV disease (high
viral load and low lymphocyte CD41 count) is associated
with kidney impairment [17, 65]. Given the imprecision of
actual GFR measurement both in HIV and non-HIV studies,
even adjusting to GFR and finding a residual association of
risk factor with cystatin C do not automatically make it a
non-GFR determinant. Although more studies are needed to
evaluate the impact of HIV viral load and CD41 count on its
level, cystatin C might be a good marker of GFR in ad-
vanced HIV disease and might detect subclinical kidney
impairment, which occurs in this situation.
Serum creatinine versus serum cystatin C in
HIV-positive subjects: and the winner is. . .
Assessment of GFR in HIV-infected patients, as in other
patients, had two different purposes. One is to provide the
most possible early diagnosis of CKD. The second one is to
detect decrease in kidney function over time (the slope of
GFR) [66]. The principal cohort studies comparing cystatin
C and creatinine in HIV patients and control subjects are
presented in Table 3. In most of them, serum creatinine
level was not different or lower in the study group than
in the control groups, whereas serum cystatin C was most
often higher in the study group. Using eGFR based on
cystatin C, the prevalence of GFR <60 mL/min/1.73 m2
is greater than using the MDRD equation, varying from 5 to
15.2% versus from 1 to 2.4% [38, 46, 56], respectively.
However, all these studies have an important limitation: the
absence of GFR measurement by a gold standard method
that can serve as a reference (the so-called ‘true GFR’).
Because of this fundamental limitation, they do not ulti-
mately permit conclusions on the superiority of cystatin C
over serum creatinine for estimating GFR.
The interest of cystatin C to follow the GFR slopes
(longitudinal follow-up) and to detect a decrease in GFR
is not well known in the HIV population. In other specific
populations of patients, cystatin C outperformed creatinine
to detect a decrease in GFR as in a cohort of diabetics [67].
Another challenge is the diagnosis of a subclinical
HAART-related kidney injury. Some commonly pre-
scribed antiretroviral therapies (e.g. tenofovir) can induce
proximal tubular injury leading to Fanconi syndrome. In
this situation, filtered cystatin C, which is not reabsorbed
by the tubule, is excreted in the urine. For this reason,
urinary cystatin C is thought to be a valuable biomarker
for detecting anti-retroviral tubular toxicity [68].
Up to now, only four studies on cystatin C in HIV-
infected subjects evaluated agreement between estimates
of GFR based on cystatin C and measured GFR. They
are summarized in Table 4.
In a cohort of 27 patients receiving HAART, Barra-
clough et al. showed that the predictive performance of
cystatin C or cystatin C-based equations to estimate GFR
was inferior to the most used creatinine-based methods (the
MDRD study equation and the Cockcroft–Gault formula).
This result must, however, be questioned since cystatin C
was measured in this study by a quantitative sandwich
enzyme immunoassay which is clearly not recommended
for measuring cystatin C [69]. Choice of the analytical
method to measure cystatin C has indeed a major impact
on the accuracy of the cystatin C-based equations [73].
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In a cohort of 22 HIV patients, Beringer et al. [70] tested
four different equations combining cystatin C and creati-
nine and found that they all provided a more accurate es-
timate as compared to the Cockcroft–Gault formula and an
equation using cystatin C alone. All these equations under-
estimated GFR measured by iothalamate. The degree of
underestimation of GFR with cystatin C was greater in
patients with detectable HIV viral load than in patients with
HIV viral load <400 copies/mL (28.8 versus 14.3%).
This difference was, however, not statistically significant.
Bonjoch et al. [61] reported that cystatin C shows the stron-
gest correlation with measured GFR by an isotopic method
(51Cr-EDTA) compared to the Cockcroft–Gault, the Chronic
Kidney Disease Epidemiology group (CKD-EPI), the MDRD
study equations and the 24-h urine creatinine clearance. GFR
was measured in 15 patients, all received HAART and 80%
had no detectable viral load for an average of 90 months.
In a South African cohort, van Deventer et al. [71] de-
veloped a new prediction equation based on cystatin C for
estimating GFR and compared performances of these new
equations to existing creatinine-based equations (MDRD,
CKD-EPI equations). One hundred black Africans patients
were included, 50 in the development dataset and 50 in the
validation dataset. In this cohort, GFR was measured by
plasma clearance of 51Cr-EDTA. Twenty patients from the
cohort were HIV positive, overall this cystatin C-based
equation was more precise than the creatinine-based equa-
tions, particularly in patients with GFR >60 mL/min/
1.73 m2. In the subgroup of HIV-positive patients, this cys-
tatin C-based equation proved to give the most accurate esti-
mate as well. Although they all used ‘true GFR’ as a
reference, these studies have in common one major limitation.
They all included a very limited number of patients and
should thus be seen as studies suggesting—not proving—the
better performance of cystatin C. Furthermore, most of the
patients included in these studies are Caucasian (except for
the South African study), HAART-treated, and had an
undetectable viral load and a CD41 lymphocyte count
>200/mm3. The performance of cystatin C may vary
with the stage of HIV infection. With a predictive
performance of 78% for MDRD, and the hypothesis of a
predictive performance of 90% for cystatin C, >250 HIV-
infected patients should be included in studies comparing
MDRD and equations based on cystatin C.
Of note, equations used to estimate GFR vary from one
study to another. Some authors used equations exclusively
based on cystatin C, while others used equations combining
cystatin C and creatinine or equation including other vari-
ables as age, gender and ethnicity. Up to now, data are
clearly insufficient to determine which equation must be
favoured in HIV patients, even if, in the general population,
interesting results have been published with the equations
combining serum creatinine and cystatin C [22]. The rela-
tive inaccuracy of estimates of GFR can be due to the
imprecision of a single GFR measurement [74, 75]. In these
four studies, the assay for measuring cystatin C concentration
was not the same and, as for serum creatinine, differences in
assays and in cystatin C calibration can severely impact the
accuracy of the equations. Further studies are needed with
greater sample size and patients with AIDS or HAART-trea-
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count. Subjects of different ethnicities should also be more
deeply studied.
Cystatin C in HIV-infected patients: a step
towards outcome prediction?
In the general population, serum cystatin C is a predictor
of CVE and of mortality [76, 77]. Cystatin C is more
strongly and more linearly associated than serum
creatinine and creatinine-estimated GFR with all-cause mor-
tality. In addition, cystatin C in combination with urine al-
bumin-to-creatinine ratio and serum creatinine is an accurate
predictor of mortality and CVE [25]. In patients with CKD,
there is a trend for a stronger association between cystatin C
and mortality than between measured GFR and mortality
[26], thereby suggesting that cystatin C could predict car-
diovascular outcomes, at least in part, independently of
its association with GFR. In the SMART trial, hs-CRP,
interleukin-6 and D-dimers were associated with all-cause
mortality [78] and risk of opportunistic diseases [79]. Serum
cystatin C was higher in the drug conservation arm [59] and
the risk of cardiovascular disease was also higher in these
patients [57]. HIV-infected subjects with high cardiovascu-
lar risk assessed by Framingham score had a higher serum
cystatin C level [80]. GFR was found to be associated
with all-cause mortality in HIV-infected subjects only when
GFR was estimated from cystatin C and not from creatinine
[27]. In the FRAM study, five-year mortality was better
predicted by cystatin C-based estimates with an increase in
absolute risk of roughly 10% for patients having an eGFR
<60 mL/min/1.73 m2 [27]. Taken together, these data sug-
gest that cystatin C might be a valuable biomarker of car-
diovascular risk assessment in HIV-seropositive patients.
The interest in cystatin C to predict outcomes in HIV-
infected subjects could justify by itself the use of cystatin C
in the follow-up of these patients. However, several issues
regarding the interest in cystatin C in HIV patients need to
be addressed first. These are summarized in Table 5.
Conclusions
Serum creatinine is far from being the ideal estimate of
GFR in HIV-infected subjects. Cystatin C appears to be
an alternative biomarker for GFR estimation. However,
studies relying on a robust methodology and comparing
estimates of GFR based on cystatin C with a reference
GFR measurement are currently missing. These studies
should calculate bias, precision and accuracy of the cystatin
C-based equations and should determine which of the var-
ious equations available must be preferred. They should
also include a sufficient number of patients, take into ac-
count the standardization of cystatin C measurement, and
use appropriate statistical analysis (Bland and Altman anal-
ysis). In addition, cystatin C might serve as a predictor of all-
cause mortality in HIV-infected patients. Whether this
Table 4. Comparison of the four studies about the predictive performance of cystatin C in estimation of GFR in HIV-infected subjectsa
N patients GFR measurement
eGFRcys
C equation eGFRcreat Results
Barraclough
et al. 2009 [69]




et al. 2010 [70]
22 Clearance of
iothalamate
eGFR ¼ 127.7 3 cysC1.17 3 age0.13
3 (0.91 if female) 3
(1.06 if African American)
MDRD, CG No statistically
significant differences
eGFRcys C,creat ¼ 177.6 3 Creat0.65
3 cysC0.57 3 age0.20 3 0.82
if female and/or 1.11
if African Americanc
Bonjoch
et al. 2010 [61]
15 51Cr-EDTA clearance CysC alone, no equation MDRD, CG, CKD-EPI CysC well correlated
with isotopic GFR
van Deventer
et al. 2011 [71]
20 51Cr-EDTA clearance eGFR ¼ 102.35 3 10(CysC 3 0.33)
3 10(0.003 3 age)
MDRD, CKD-EPI eGFRcys C more
accurate than eGFRcreat
aDTPA, Diethylene Triamine Pentaacetic Acid.
bMacisaac RJ et al. [72].
cStevens LA et al. [22].
Table 5. Critical questions about the use of cystatin C in HIV-infected patients
The cost in comparison with the dosage of serum creatinine
Could an early diagnosis of CKD-infected patients affect the outcome of the HIV infection?
No eGFRcys equations are up to now validated in this population
Should cystatin be used in combination with creatinine?
Are the associations between non-HIV-related factors such as CRP level and smoking status only dependent on GFR?
Do HIV viral load and lymphocytes CD41 count affect cystatin C level only in association with kidney function?
Do physicians need a novel GFR estimate or a predictor of clinical outcomes?
Should physicians use the same GFR estimates for all HIV-infected patients?
Is it feasible to monitor kidney function with such an assay in developing countries where the majority of HIV-infected people live?
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ability to predict patient outcome will extend to cardiovas-
cular morbi-mortality and CKD progression still has to be
evaluated. Given that HIV-infected patients are at in-
creased risk of CVE, cystatin C might be particularly
valuable in this population. Whatever the role played by
cystatin C in the future for the care of HIV-infected pa-
tients, financial issues will have to be addressed. Standar-
dized measurement of cystatin C will be very soon easily
available but will remain expensive in comparison to the
measurement of serum creatinine. The added value of cys-
tatin C will have to be both clinically significant and eco-
nomically acceptable for its widespread diffusion,
particularly in developing countries.
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